文献速递皮肤肿瘤

浅表性基底细胞癌光动力、咪喹莫特与氟尿嘧啶五年随机对照试验结果

Five-Year Results of a Randomized Controlled Trial Comparing Effectiveness of Photodynamic Therapy, Topical Imiquimod, and Topical 5-Fluorouracil in Patients with Superficial Basal Cell Carcinoma.
PubMed 文献 · J Invest Dermatol · 2017-10-16

一项前瞻性、非劣效性、随机对照多中心试验纳入601例浅表性基底细胞癌患者,5年随访意向性分析显示,5%咪喹莫特乳膏的肿瘤无生存概率为80.5%,优于氨基酮戊酸光动力疗法的62.7%和5-氟尿嘧啶的70.0%;咪喹莫特相对光动力的治疗失败风险比为0.48(P<0.001),相对5-氟尿嘧啶为0.65(P=0.04)。结论认为5%咪喹莫特乳膏疗效最优,可作为多数原发性浅表性基底细胞癌非侵入性治疗的首选。

要点

  • 5年肿瘤无生存概率:咪喹莫特80.5%,5-氟尿嘧啶70.0%,光动力62.7%。
  • 咪喹莫特治疗失败风险显著低于光动力(HR=0.48,P<0.001)和5-氟尿嘧啶(HR=0.65,P=0.04)。
  • 5%咪喹莫特乳膏可作为多数原发性浅表性基底细胞癌非侵入性治疗的首选。

核心结论

  • 治疗5年后,5%咪喹莫特乳膏在浅表性基底细胞癌的疗效上优于氨基酮戊酸光动力疗法和5-氟尿嘧啶乳膏。
  • 研究者认为5%咪喹莫特乳膏可作为多数原发性浅表性基底细胞癌非侵入性治疗的首选。

研究设计与样本

  • 前瞻性、非劣效性、随机对照多中心试验,纳入601例浅表性基底细胞癌患者。
  • 本次报告为治疗5年后的意向性分析随访结果。

主要发现

  • 5年肿瘤无生存概率:光动力组62.7%(95%CI 55.3-69.2),咪喹莫特组80.5%(95%CI 74.0-85.6),5-氟尿嘧啶组70.0%(95%CI 62.9-76.0)。
  • 与光动力相比,咪喹莫特治疗失败的风险比为0.48(95%CI 0.32-0.71,P<0.001),5-氟尿嘧啶为0.74(95%CI 0.53-1.05,P=0.09)。
  • 与5-氟尿嘧啶相比,咪喹莫特治疗失败的风险比为0.65(95%CI 0.43-0.98,P=0.04)。

关键数值与推荐

  • 5年肿瘤无生存概率:咪喹莫特80.5%(95%CI 74.0-85.6),5-氟尿嘧啶70.0%(95%CI 62.9-76.0),光动力62.7%(95%CI 55.3-69.2)。
  • 咪喹莫特对比光动力的治疗失败HR=0.48(95%CI 0.32-0.71,P<0.001)。
  • 5-氟尿嘧啶对比光动力的治疗失败HR=0.74(95%CI 0.53-1.05,P=0.09)。
  • 咪喹莫特对比5-氟尿嘧啶的治疗失败HR=0.65(95%CI 0.43-0.98,P=0.04)。

临床怎么用

  • 对于多数原发性浅表性基底细胞癌,5%咪喹莫特乳膏可作为非侵入性治疗的首选。
  • 5-氟尿嘧啶乳膏和氨基酮戊酸光动力疗法仍为可选的非侵入性治疗,但5年疗效低于咪喹莫特。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

For the treatment of superficial basal cell carcinoma, a prospective, noninferiority, randomized controlled multicenter trial with 601 patients showed that 5% imiquimod cream was superior and 5-fluorouracil cream not inferior to methyl aminolevulinate photodynamic therapy (MAL-PDT) at 1 and 3 years after treatment. No definite conclusion could be drawn regarding the superiority of imiquimod over 5-fluorouracil. We now present the 5-year follow-up results according to the intention-to-treat analysis. Five years after treatment, the probability of tumor-free survival was 62.7% for methyl aminolevulinate photodynamic therapy (95% confidence interval [CI] = 55.3-69.2), 80.5% for imiquimod (95% CI = 74.0-85.6), and 70.0% for 5-fluorouracil (95% CI = 62.9-76.0). The hazard ratio for treatment failure of imiquimod and 5-fluorouracil were 0.48 (95% CI = 0.32-0.71, P < 0.001) and 0.74 (95% CI = 0.53-1.05, P = 0.09), respectively, when compared with methyl aminolevulinate photodynamic therapy. Compared with 5-fluorouracil, imiquimod showed a hazard ratio of 0.65 (95% CI 0.43-0.98, P = 0.04). In conclusion, 5 years after treatment, the results of this trial show that 5% imiquimod cream is superior to both methyl aminolevulinate photodynamic therapy and 5-fluorouracil cream in terms of efficacy for superficial basal cell carcinoma. We therefore consider 5% imiquimod cream as the first choice for noninvasive treatment in most primary superficial basal cell carcinomas.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Jansen MHE, Mosterd K, Arits AHMM, et al. Five-Year Results of a Randomized Controlled Trial Comparing Effectiveness of Photodynamic Therapy, Topical Imiquimod, and Topical 5-Fluorouracil in Patients with Superficial Basal Cell Carcinoma. J Invest Dermatol. 2017. PMID: 29045820. doi:10.1016/j.jid.2017.09.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。